Phase III double-blind study of TAK-536CCB in patients with grade I or II essential hypertensio
Phase 3
- Conditions
- Hypertension
- Registration Number
- JPRN-jRCT2080221566
- Lead Sponsor
- TAKEDA PHARMACEUTICAL COMPANY LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Main inclusion criteria:
1. Grade I or II essential hypertension.
Exclusion Criteria
Main exclusion criteria:
1.Secondary hypertension, grade III hypertension, or malignant hypertension
2.Heart disease, cerebrovascular disease, vascular disease, or advanced hypertensive retinopathy
3.Hyperkalemia,etc
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method